MCID: MYL006
MIFTS: 60

Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 52 29 54 15 71
Myeloid Leukaemia 12 32
Myeloid Granulocytic Leukaemia 12
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukaemia Myelogenous 12
Leukemia Myelogenous 12
Leukemia, Myeloid 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8692
ICD9CM 34 205
MeSH 43 D007951
NCIt 49 C3172
SNOMED-CT 67 188732008 37810007
ICD10 32 C92 C92.9
UMLS 71 C0023470

Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid leukaemia, is related to core binding factor acute myeloid leukemia and cytogenetically normal acute myeloid leukemia. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Dopamine and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1304)
# Related Disease Score Top Affiliating Genes
1 core binding factor acute myeloid leukemia 35.4 RUNX1 KIT FLT3 CEBPA CBFB
2 cytogenetically normal acute myeloid leukemia 35.3 NPM1 FLT3 CEBPA
3 atypical chronic myeloid leukemia 35.3 U2AF1 RUNX1 FLT3 ETV6 ABL1
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 35.1 RUNX1 MYH11 KIT FLT3 ETV6 CBFB
5 childhood acute myeloid leukemia 35.0 NUP98 NSD1 NPM1 KIT FLT3
6 leukemia, chronic myeloid 35.0 U2AF1 RUNX1 PTPN11 NUP98 NPM1 MCL1
7 leukemia, acute myeloid 34.9 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
8 cebpa-associated familial acute myeloid leukemia 34.8 RUNX1 NPM1 KIT GATA2 FLT3 ETV6
9 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.8 RUNX1T1 RUNX1 KIT FLT3 CEBPA
10 acute promyelocytic leukemia 34.6 U2AF1 RUNX1T1 RUNX1 NUP98 NPM1 GATA2
11 acute myeloblastic leukemia with maturation 34.5 NPM1 KIT FLT3
12 acute erythroid leukemia 34.4 GATA2 CEBPA
13 myelodysplastic syndrome 33.9 U2AF1 RUNX1 PTPN11 NUP98 NSD1 NPM1
14 leukemia 33.8 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
15 myeloid sarcoma 33.7 U2AF1 NPM1 KIT FLT3
16 essential thrombocythemia 33.6 U2AF1 PTPN11 KIT ABL1
17 myeloproliferative neoplasm 33.6 U2AF1 RUNX1 PTPN11 KIT FLT3 ETV6
18 acute myeloblastic leukemia without maturation 33.6 NPM1 FLT3
19 megakaryocytic leukemia 33.6 U2AF1 RUNX1 MIR100HG
20 polycythemia vera 33.5 U2AF1 PTPN11 KIT FLT3 ETV6 ABL1
21 8p11 myeloproliferative syndrome 33.5 RUNX1 KIT FLT3
22 childhood leukemia 33.5 RUNX1 PTPN11 ETV6 ABL1
23 leukemia, acute monocytic 33.5 U2AF1 NUP98 FLT3
24 myelodysplastic/myeloproliferative neoplasm 33.5 U2AF1 PTPN11 KIT FLT3 ETV6 ABL1
25 juvenile myelomonocytic leukemia 33.4 U2AF1 RUNX1 PTPN11 FLT3
26 acute leukemia 32.7 RUNX1T1 RUNX1 NUP98 NPM1 KIT GATA2
27 leukemia, acute lymphoblastic 32.4 U2AF1 RUNX1 PTPN11 MCL1 KIT GATA2
28 myelofibrosis 32.2 U2AF1 RUNX1 NPM1 KIT GATA2 FLT3
29 pancytopenia 32.2 U2AF1 RUNX1 KIT FLT3
30 chronic myelomonocytic leukemia 32.1 U2AF1 RUNX1 PTPN11 NUP98 NPM1 KIT
31 leukemia, chronic lymphocytic 32.1 U2AF1 PTPN11 NPM1 MCL1 KIT FLT3
32 mastocytosis 32.0 PTPN11 KIT FLT3
33 wilms tumor 1 32.0 U2AF1 NPM1 KIT FLT3 CEBPA
34 myeloma, multiple 31.9 U2AF1 PTPN11 MCL1 KIT FLT3 ABL1
35 systemic mastocytosis 31.9 U2AF1 PTPN11 KIT
36 chronic leukemia 31.8 U2AF1 KIT FLT3 ABL1
37 precursor t-cell acute lymphoblastic leukemia 31.7 NUP98 FLT3 ETV6 ABL1
38 leukemia, acute lymphoblastic 3 31.7 RUNX1 FLT3 ETV6 ABL1
39 hematologic cancer 31.7 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NPM1
40 lymphoma, non-hodgkin, familial 31.6 U2AF1 NPM1 MCL1 FLT3 ETV6
41 blood platelet disease 31.6 U2AF1 RUNX1 KIT FLT3
42 t-cell acute lymphoblastic leukemia 31.6 U2AF1 RUNX1 NUP98 FLT3 ETV6 ABL1
43 gastrointestinal stromal tumor 31.5 MYH11 MCL1 KIT FLT3 ABL1
44 childhood acute lymphocytic leukemia 31.4 U2AF1 MCL1 ETV6 ABL1
45 refractory cytopenia with multilineage dysplasia 31.3 U2AF1 GATA2
46 chronic eosinophilic leukemia 31.2 U2AF1 KIT FLT3 ETV6 ABL1
47 aggressive systemic mastocytosis 31.0 U2AF1 RUNX1 PTPN11 KIT FLT3
48 sm-ahnmd 31.0 U2AF1 KIT
49 bone marrow cancer 30.8 U2AF1 NPM1 MCL1 KIT FLT3 ABL1
50 mast cell neoplasm 30.8 U2AF1 KIT FLT3

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.8 U2AF1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.8 U2AF1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.8 ABL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 KIT
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.8 U2AF1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.8 ABL1 KIT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.8 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.8 CBFB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.8 U2AF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.8 ABL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.8 ABL1 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.8 ABL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.8 CBFB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.8 ABL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.8 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.8 CEBPA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.8 CBFB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.8 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.8 CEBPA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.8 CBFB
21 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.8 ABL1 KIT U2AF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.8 CBFB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.8 U2AF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.8 U2AF1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.8 KIT
27 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
28 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
29 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
30 Increased shRNA abundance GR00327-A 9.43 CEBPA ERG FLT3 MCL1 MYH11 PTPN11
31 Decreased replication of vaccinia virus (VACV) GR00362-A 9.26 NUP98 RUNX1

MGI Mouse Phenotypes related to Myeloid Leukemia:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 ABL1 CBFB CEBPA ERG ETV6 FLT3
2 cardiovascular system MP:0005385 10.33 ABL1 CBFB CEBPA ERG ETV6 GATA2
3 hematopoietic system MP:0005397 10.33 ABL1 CBFB CEBPA ERG ETV6 FLT3
4 growth/size/body region MP:0005378 10.32 ABL1 CBFB CEBPA ERG ETV6 FLT3
5 embryo MP:0005380 10.29 ABL1 CBFB ERG ETV6 GATA2 KIT
6 immune system MP:0005387 10.28 ABL1 CBFB CEBPA ERG ETV6 FLT3
7 endocrine/exocrine gland MP:0005379 10.27 ABL1 CBFB CEBPA ERG ETV6 FLT3
8 mortality/aging MP:0010768 10.22 ABL1 CBFB CEBPA ERG ETV6 FLT3
9 integument MP:0010771 10.14 CBFB CEBPA ERG ETV6 KIT MCL1
10 digestive/alimentary MP:0005381 10.13 ABL1 CBFB CEBPA ETV6 KIT MYH11
11 liver/biliary system MP:0005370 9.97 ABL1 CBFB CEBPA GATA2 KIT NPM1
12 neoplasm MP:0002006 9.91 CBFB CEBPA ERG ETV6 FLT3 KIT
13 no phenotypic analysis MP:0003012 9.76 CBFB CEBPA ETV6 FLT3 KIT NSD1
14 normal MP:0002873 9.7 ABL1 CBFB CEBPA ERG ETV6 GATA2
15 respiratory system MP:0005388 9.23 ABL1 CBFB CEBPA ERG KIT MYH11

Drugs & Therapeutics for Myeloid Leukemia

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Lenalidomide Approved Phase 4 191732-72-6 216326
6 Dopamine Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Neurotransmitter Agents Phase 4
9 Antidepressive Agents Phase 4
10 Central Nervous System Stimulants Phase 4
11 Cholinergic Agents Phase 4
12 Nicotinic Agonists Phase 4
13 Imatinib Mesylate Phase 4 220127-57-1 123596
14 Tin Fluorides Phase 4
15 Angiogenesis Inhibitors Phase 4
16
Lorazepam Approved Phase 3 846-49-1 3958
17
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
18
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
19
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
20
Idarubicin Approved Phase 3 58957-92-9 42890
21 Orange Approved Phase 2, Phase 3
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
23
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
24
Ribavirin Approved Phase 3 36791-04-5 37542
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
27
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
28
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
29
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
30
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5362032
31
Enalaprilat Approved Phase 3 76420-72-9 6917719
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
33
Acyclovir Approved Phase 3 59277-89-3 2022
34
Clove Approved Phase 2, Phase 3 84961-50-2
35
Dalteparin Approved Phase 3 9005-49-6
36
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
37
Tazobactam Approved Phase 3 89786-04-9 123630
38
Vancomycin Approved Phase 3 1404-90-6 14969 441141
39
Piperacillin Approved Phase 3 66258-76-2 43672
40
Palivizumab Approved, Investigational Phase 3 188039-54-5
41
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
42
Morphine Approved, Investigational Phase 3 57-27-2 5288826
43
Thioguanine Approved Phase 3 154-42-7 2723601
44
Atorvastatin Approved Phase 3 134523-00-5 60823
45
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
46
Ofloxacin Approved Phase 3 82419-36-1 4583
47
Captopril Approved Phase 3 62571-86-2 44093
48
Nalbuphine Approved Phase 3 20594-83-6 5311304 5360630
49
tannic acid Approved Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 3486)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
2 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
3 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
6 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
7 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
8 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
9 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
10 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
11 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
12 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
13 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
14 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Completed NCT02875743 Phase 4 Posaconazole
15 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
16 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
17 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
18 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
19 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
20 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Completed NCT01243489 Phase 4
21 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
22 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
23 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
24 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
25 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
26 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
27 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
28 A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
29 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
30 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
31 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
32 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
33 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
34 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
35 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV) Completed NCT01578213 Phase 4 Imatinib mesylate
36 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
37 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
38 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
39 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
40 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
41 A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia Completed NCT02267993 Phase 4 recombinant human thrombopoietin
42 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
43 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
44 Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic‐Phase Chronic Myeloid Leukemia (CML-CP) Recruiting NCT04155411 Phase 4 Dasatinib
45 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
46 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
47 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
48 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
49 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
50 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


dasatinib
imatinib
ponatinib

Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

19
Myeloid Tissue

MalaCards organs/tissues related to Myeloid Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, B Cells

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 37767)
# Title Authors PMID Year
1
Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. 54 61
20042850 2010
2
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. 61 54
20445327 2010
3
Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation. 54 61
19917671 2010
4
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 54 61
19880492 2010
5
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 54 61
20084277 2010
6
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 54 61
19935430 2010
7
Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells. 61 54
19699159 2009
8
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 61 54
19734451 2009
9
Decreased TLR4 gene expression in leukemic leukocyte populations. 61 54
19631641 2009
10
[Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. 54 61
19860196 2009
11
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. 61 54
19339050 2009
12
Retraction notice to "The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells" [Blood Cells Mol. Dis. 39 (2007) 307-315]. 54 61
19388154 2009
13
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 61 54
19407318 2009
14
[Apoptosis of human myeloid leukemia cell line HL-60 cells induced by siRNA targeting gene c-myc]. 61 54
19379561 2009
15
Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. 54 61
19429444 2009
16
[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. 54 61
19671288 2009
17
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. 54 61
19058874 2009
18
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. 54 61
19960054 2009
19
EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. 54 61
18815193 2008
20
AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. 54 61
18687517 2008
21
Expression profile of CREB knockdown in myeloid leukemia cells. 54 61
18801183 2008
22
DMNQ-S17 inhibits constitutive NF-kappaB activation leading to induction of apoptosis through the activation of caspase-3 in human myeloid leukemia U937 cells. 54 61
18718843 2008
23
PR1 vaccination in myeloid malignancies. 61 54
18767937 2008
24
Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. 54 61
18059480 2008
25
[Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells]. 54 61
18822958 2008
26
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. 54 61
18569848 2008
27
Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. 54 61
18455519 2008
28
TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. 61 54
18294958 2008
29
Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. 61 54
18483256 2008
30
Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1. 61 54
18345608 2008
31
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. 61 54
18414055 2008
32
Evidence for CALM in directing VAMP2 trafficking. 54 61
18182011 2008
33
CREB is a critical regulator of normal hematopoiesis and leukemogenesis. 54 61
17975014 2008
34
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]. 54 61
18476539 2007
35
Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells. 54 61
17664007 2007
36
The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells. 61 54
17644368 2007
37
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. 54 61
17917967 2007
38
Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. 54 61
17081606 2007
39
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. 61 54
17644747 2007
40
Evidence that the Pim1 kinase gene is a direct target of HOXA9. 54 61
17327400 2007
41
Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. 54 61
17583492 2007
42
CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. 54 61
17431504 2007
43
Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis. 61 54
17381798 2007
44
Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. 61 54
17604209 2007
45
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. 61 54
17213995 2007
46
Identification of novel nuclear localization signals of Drosophila myeloid leukemia factor. 61 54
18159124 2007
47
Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. 54 61
17095538 2007
48
Characterization of the Drosophila myeloid leukemia factor. 61 54
17121541 2006
49
Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. 54 61
17008314 2006
50
Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. 54 61
17043020 2006

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.93 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
2 nucleus GO:0005634 9.53 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
3 core-binding factor complex GO:0016513 8.96 RUNX1 CBFB

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.1 MLF1 MCL1 GATA2 FLT3 ETV6 ERG
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 RUNX1 NSD1 GATA2 ETV6 CEBPA CBFB
3 regulation of transcription by RNA polymerase II GO:0006357 9.95 RUNX1 NPM1 KIT ETV6 ERG CEBPA
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.92 RUNX1 NPM1 GATA2 ETV6 ERG CEBPA
5 regulation of transcription, DNA-templated GO:0006355 9.91 RUNX1T1 RUNX1 NSD1 MLF1 GATA2 ETV6
6 cytokine-mediated signaling pathway GO:0019221 9.77 PTPN11 MCL1 KIT FLT3 CEBPA
7 interleukin-6-mediated signaling pathway GO:0070102 9.63 PTPN11 CEBPA
8 cell fate determination GO:0001709 9.63 MCL1 GATA2
9 regulation of keratinocyte differentiation GO:0045616 9.62 RUNX1 CBFB
10 megakaryocyte development GO:0035855 9.61 PTPN11 KIT
11 definitive hemopoiesis GO:0060216 9.61 GATA2 CBFB
12 cell maturation GO:0048469 9.61 GATA2 CEBPA CBFB
13 regulation of regulatory T cell differentiation GO:0045589 9.6 RUNX1 CBFB
14 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.59 RUNX1 CBFB
15 hematopoietic stem cell proliferation GO:0071425 9.58 RUNX1 ETV6
16 regulation of bicellular tight junction assembly GO:2000810 9.58 RUNX1 CBFB
17 regulation of response to DNA damage stimulus GO:2001020 9.57 MCL1 ABL1
18 regulation of B cell receptor signaling pathway GO:0050855 9.56 RUNX1 CBFB
19 regulation of myeloid cell differentiation GO:0045637 9.55 RUNX1 CBFB
20 Bergmann glial cell differentiation GO:0060020 9.52 PTPN11 ABL1
21 lymphocyte differentiation GO:0030098 9.51 FLT3 CBFB
22 regulation of cytokine-mediated signaling pathway GO:0001959 9.49 RUNX1 CBFB
23 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.48 RUNX1 CBFB
24 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.46 RUNX1 CBFB
25 hemopoiesis GO:0030097 9.46 RUNX1 KIT GATA2 FLT3
26 regulation of hematopoietic stem cell differentiation GO:1902036 9.26 RUNX1 GATA2 CBFB ABL1
27 myeloid progenitor cell differentiation GO:0002318 8.8 MLF1 KIT FLT3

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 U2AF1 RUNX1T1 RUNX1 PTPN11 NUP98 NSD1
2 DNA binding GO:0003677 10.02 RUNX1T1 RUNX1 MLF1 GATA2 ETV6 ERG
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.91 RUNX1 GATA2 ETV6 ERG CEBPA CBFB
4 chromatin binding GO:0003682 9.8 NSD1 NPM1 GATA2 ERG CEBPA
5 protein domain specific binding GO:0019904 9.76 PTPN11 MLF1 ETV6 ABL1
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.72 RUNX1 GATA2 ETV6 ERG CEBPA
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.63 RUNX1 NSD1 GATA2 ETV6 ERG CEBPA
8 DNA-binding transcription factor activity GO:0003700 9.5 RUNX1T1 RUNX1 GATA2 ETV6 ERG CEBPA
9 transcription coactivator activity GO:0003713 9.02 NUP98 NPM1 CEBPA CBFB ABL1

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....